Chabiotech Co.,Ltd. (KOSDAQ:085660)
15,480
-160 (-1.02%)
At close: Dec 5, 2025
Chabiotech Revenue
Chabiotech had revenue of 318.68B KRW in the quarter ending September 30, 2025, with 17.15% growth. This brings the company's revenue in the last twelve months to 1.20T, up 18.61% year-over-year. In the year 2024, Chabiotech had annual revenue of 1.05T with 9.55% growth.
Revenue (ttm)
1,197.69B
Revenue Growth
+18.61%
P/S Ratio
0.98
Revenue / Employee
4.31B
Employees
278
Market Cap
1,175.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,045.05B | 91.10B | 9.55% |
| Dec 31, 2023 | 953.95B | 109.37B | 12.95% |
| Dec 31, 2022 | 844.58B | 117.11B | 16.10% |
| Dec 31, 2021 | 727.48B | 62.76B | 9.44% |
| Dec 31, 2020 | 664.72B | 130.11B | 24.34% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |